About US
Contact us
-
Report: Favourable market environment to drive Australian pharmaceutical industry to $25bn by 2020Good market access and government’s welfare reforms such as subsidies for prescription drugs are expected to drive the pharmaceutical market in Australia to $25bn in value by 2020, according to a repo2016/9/26
-
EC grants marketing authorisation for Aptalis’s Truberzi to treat IBS-DThe European Commission (EC) has granted marketing authorisation for Aptalis’s Truberzi (eluxadoline) in Europe. Rights to the drug will shortly be transferred back to Allergan, following thesale of2016/9/23
-
Sanaria receives FDA fast-track designation for malaria vaccineSanaria has received fast-track designation from the US Food and Drug Administration (FDA) for candidate malaria vaccine PfSPZ. PfSPZ is currently in clinical trials that are intended to finalise an2016/9/23
-
Gilead faces another bid for hep C royalties as U of MN sues for patent infringementThe University of Minnesota wants a piece of Gilead Sciences’ megablockbuster hepatitis C business. The school sued Gilead for patent infringement Monday, claiming that the drugmaker’s sofosbuvir-bas2016/9/22
-
AstraZeneca settles lingering China bribery case with SECAstraZeneca has often been pointed to as a company that knows how to succeed in emerging markets like China, and CEO Pascal Soriot has made growth in these areas as one element of in his 5-part growth2016/9/22
-
Mylan faces more EpiPen scrutiny as House committee demands infoIf Mylan was hoping that its new EpiPen copay assistance and authorized generic would stave off government probing, then it’s hoping in vain. Another congressional commitee has piled on to Mylan and2016/9/21
-
AG lambasts Purdue for fighting his opioid marketing probePurdue Pharma’s highly addictive opioid Oxycontin has led to the company beingmaligned in lawsuits, by law enforcement officials and state and federal lawmakers. Now the Attorney General of New Hampsh2016/9/21
-
Insys sued by Illinois AG for off-label marketing of Subsys opioid sprayAfter a former Insys Therapeutics ($INSY) sales rep admitted she had paid kickbacks to doctors to prescribe the company's sprayed cancer pain opioid fentanyl for off-label uses, it was just a matter o2016/9/20
-
Celgene off-label marketing lawsuit documents unsealedCelgene ($CELG) has successfully fought off several lawsuits suggesting the success of its blockbuster multiple myeloma meds Revlimid and Thalomid relied on aggressive off-label marketing.A California2016/9/20
-
Hillary's latest drug-price tweet put the fear of government action into biopharma stocksThe power of a Hillary Clinton tweet was proven again Wednesday, when the presidential candidate sent out a missive about drug prices. Biotech stocks, down. Pharma stocks, down. Even U.K. drugmakers s2016/9/19